DR info

臨床試験数 : 126 / 薬物数 : 135 - (DrugBank : 42) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 162

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

(R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE
   Cytokinetics, Inc.
      2021   Phase 2   EUCTR2020-003571-17-ES   Italy;Spain;United States;
      2020   Phase 2   EUCTR2019-002785-12-GB   Italy;Netherlands;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002785-12-ES   Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 2   EUCTR2019-002785-12-NL   Italy;Netherlands;Spain;United Kingdom;United States;
(R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1H-PYRAZOLE-4-CARBOXAMIDE
   CYTOKINETICS, INC.
      2021   Phase 2   EUCTR2020-003571-17-IT   Italy;Spain;United States;
      2020   Phase 2   EUCTR2019-002785-12-IT   Italy;Netherlands;Spain;United Kingdom;United States;
(R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1HPYRAZOLE-4-CARBOXAMIDE
   CYTOKINETICS, INC.
      2021   Phase 2   EUCTR2020-003571-17-IT   Italy;Spain;United States;
1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride
   University College London (UCL)
      2011   -   EUCTR2011-000038-12-GB   United Kingdom;
3D electrocardiographic mapping (ECM)
   University Hospital, Bordeaux
      2015   -   NCT02559726   France;
Adenosine
   Duke University
      2017   Phase 4   NCT03249272   United States;
Air
   University Hospital, Bordeaux
      2019   -   NCT04129905   France;
Alcohol
   Beijing Anzhen Hospital, Capital Medical University
      2021   -   ChiCTR2000041464   China;
   Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
      2020   Phase 0   ChiCTR2000033626   China;
Alcohol Septal Ablation
   St. Antonius Hospital
      2021   -   NCT04684290   Netherlands;
Alcohol septal ablation
   Steen Hvitfeldt Poulsen
      2019   -   NCT04066777   Denmark;
Amyl nitrite inhalation
   Mayo Clinic
      2021   -   NCT04905173   United States;
Antiarrhythmic drugs
   Institute of Cardiology, Warsaw, Poland
      2009   Phase 3   NCT00821353   Poland;
Aspirin
   Ottawa Heart Institute Research Corporation
      2016   Phase 3   NCT02674958   Canada;
Atorvastatin
   University of Calgary
      2007   Phase 3   NCT00317967   Canada;
B-lines SE
   Fatebenefratelli Hospital
      2016   -   NCT03049995   Italy;
BNP blood sample test
   University Hospital, Bordeaux
      2019   -   NCT04129905   France;
C01EB18
   OSPEDALE SAN RAFFAELE
      2016   Phase 2   EUCTR2015-004402-42-IT   Italy;
CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4- (trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4- (trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one
   Gilead Sciences, Inc.
      2015   Phase 2   EUCTR2013-004429-97-GB   Australia;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one
   Gilead Sciences, Inc.
      2015   Phase 2   EUCTR2013-004429-97-NL   France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
      2015   Phase 2   EUCTR2013-004429-97-IT   France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
      2015   Phase 2   EUCTR2013-004429-97-GB   Australia;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
CK-3773274
   CYTOKINETICS, INC.
      2021   Phase 2   EUCTR2020-003571-17-IT   Italy;Spain;United States;
      2020   Phase 2   EUCTR2019-002785-12-IT   Italy;Netherlands;Spain;United Kingdom;United States;
   Cytokinetics, Inc.
      2021   Phase 2   EUCTR2020-003571-17-ES   Italy;Spain;United States;
      2020   Phase 2   EUCTR2019-002785-12-GB   Italy;Netherlands;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-002785-12-ES   Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 2   EUCTR2019-002785-12-NL   Italy;Netherlands;Spain;United Kingdom;United States;
   Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
      2021   Phase 1   NCT04783766   China;
CK-3773274 (10 - 30 mg)
   Cytokinetics
      2020   Phase 2   NCT04219826   Italy;Netherlands;Spain;United States;
CK-3773274 (5 - 15 mg)
   Cytokinetics
      2020   Phase 2   NCT04219826   Italy;Netherlands;Spain;United States;
CK-3773274 (5 - 20 mg)
   Cytokinetics
      2021   Phase 2   NCT04848506   Italy;Spain;United States;
CK-3773274 (5 mg, 10 mg, 15 mg and 20 mg)
   Cytokinetics
      2022   Phase 3   NCT05186818   United States;
CK-3773274 - Granules in Capsule
   Cytokinetics
      2018   Phase 1   NCT03767855   United States;
CK-3773274 - Tablets
   Cytokinetics
      2018   Phase 1   NCT03767855   United States;
CT-G20
   Celltrion
      2020   Phase 1   NCT04418297   Korea, Republic of;Poland;United States;
Candesartan
   Charles University, Czech Republic
      2007   Phase 2   NCT00430833   Czech Republic;
   The First Affiliated Hospital, Sun Yat-sen University
      2018   Phase 4 study   ChiCTR-IIR-17013661   China;
Carnitine
   University Health Network, Toronto
      2013   Phase 4   NCT01904396   Canada;
Cibenzoline
   TOA EIYO LTD.
      2019   Phase 2   JPRN-JapicCTI-194910   Japan;
Coronary flow reserve SE
   Fatebenefratelli Hospital
      2016   -   NCT03049995   Italy;
Cufence
   Manchester University NHS Foundation Trust
      2020   Phase 2   EUCTR2020-002242-17-GB   United Kingdom;
Cyclosporine A
   National Heart, Lung, and Blood Institute (NHLBI)
      1999   Phase 2   NCT00001965   United States;
Diastolic function SE
   Fatebenefratelli Hospital
      2016   -   NCT03049995   Italy;
Diltiazem
   Brigham and Women's Hospital
      2006   Phase 2/Phase 3   NCT00319982   United States;
Diovan
   National Heart, Lung, and Blood Institute / National Institutes of Health
      2016   Phase 2   EUCTR2015-002283-16-DK   Denmark;
Dobutamine
   University of Aarhus
      2011   Phase 4   NCT01375335   Denmark;
Echo and myocardial contrast echocardiography perfusion imaging
   Oregon Health and Science University
      2015   -   NCT02560467   United States;
Echocardiography (TEE)
   University Hospital, Bordeaux
      2015   -   NCT02559726   France;
Eleclazine
   Gilead Sciences
      2015   Phase 2/Phase 3   NCT02291237   Australia;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
Endothelial function biomarkers
   University Hospital, Bordeaux
      2019   -   NCT04129905   France;
Entresto
   Novartis Farmacéutica, S.A.
      2020   Phase 2   EUCTR2019-003098-24-ES   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
   Novartis Pharma AG
      2020   Phase 2   EUCTR2019-003098-24-GR   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003098-24-GB   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003098-24-FI   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-003098-24-DE   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
Esmolol
   Meshalkin Research Institute of Pathology of Circulation
      2021   Phase 4   NCT05073094   Russian Federation;
GS-6615
   Gilead Sciences, Inc.
      2015   Phase 2   EUCTR2013-004429-97-NL   France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
      2015   Phase 2   EUCTR2013-004429-97-IT   France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
GS-6615 3 mg Pink
   Gilead Sciences, Inc.
      2015   Phase 2   EUCTR2013-004429-97-GB   Australia;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
GS-6615 3 mg White
   Gilead Sciences, Inc.
      2015   Phase 2   EUCTR2013-004429-97-GB   Australia;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
GS-6615 6 mg White
   Gilead Sciences, Inc.
      2015   Phase 2   EUCTR2013-004429-97-GB   Australia;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
Gold
   Beijing Chaoyang Hospital, Capital Medical University
      2021   Phase 0   ChiCTR2100048388   China;
Gutron 2,
   CHU de Bordeaux
      2015   -   EUCTR2015-003521-34-FR   France;
Hyperpolarized 13C-Pyruvate
   University of Texas Southwestern Medical Center
      2018   -   NCT03057002   United States;
IMB-1018972
   Imbria Pharmaceuticals, Inc.
      2021   Phase 2   NCT04826185   United Kingdom;United States;
IMUKIN - 6 FLACONI 0.5 ML 100 MCG
   ASSOCIAZIONE LA NOSTRA FAMIGLIA - SEZIONE SCIENTIFICA I.R.C.C.S. E.MEDEA
      2016   Phase 2   EUCTR2015-002432-40-IT   Italy;
Insertable cardiac monitor
   Region Gävleborg
      2017   -   NCT03259113   Sweden;
LCZ696
   Novartis Farmacéutica, S.A.
      2020   Phase 2   EUCTR2019-003098-24-ES   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
   Novartis Pharma AG
      2020   Phase 2   EUCTR2019-003098-24-GR   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003098-24-GB   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003098-24-FI   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-003098-24-DE   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
   Novartis Pharmaceuticals
      2020   Phase 2   NCT04164732   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
Left ventricular contractile reserve SE
   Fatebenefratelli Hospital
      2016   -   NCT03049995   Italy;
Left ventricular outflow tract gradient SE
   Fatebenefratelli Hospital
      2016   -   NCT03049995   Italy;
Losartan
   Henning Bundgaard
      2011   Phase 2   NCT01447654   Denmark;
   Massachusetts General Hospital
      2007   Phase 2   NCT01150461   United States;
   National Heart, Lung, and Blood Institute (NHLBI)
      1996   -   NCT00001534   United States;
Losartan Bluefish
   Hjertemedicinsk klinik B, 2142, Rigshospitalet
      2011   -   EUCTR2011-001191-19-DK   Denmark;
MEK162
   Array Biopharma, now a wholly owned subsidiary of Pfizer
      2012   Phase 2   NCT01556568   United Kingdom;United States;
   Novartis Pharma Services AG
      2012   -   EUCTR2011-003392-10-GB   United Kingdom;United States;
METOPROLOL SUCCINATE
   Aarhus University Hospital
      2018   Phase 2   EUCTR2017-004478-32-DK   Denmark;
MIDODRINE HYDROCHLORIDE
   CHU de Bordeaux
      2015   -   EUCTR2015-003521-34-FR   France;
MYK-461
   MYOKARDIA, INC.
      2019   Phase 3   EUCTR2018-004039-64-IT   Belgium;Czechia;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002530-23-IT   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
   MyoKardia, Inc.
      2019   Phase 3   EUCTR2018-004039-64-PT   Belgium;Czechia;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004039-64-PL   Belgium;Czechia;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004039-64-NL   Belgium;Czechia;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004039-64-GB   Belgium;Czech Republic;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004039-64-ES   Belgium;Czech Republic;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004039-64-DK   Belgium;Czechia;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004039-64-DE   Belgium;Czechia;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004039-64-BE   Belgium;Czechia;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002530-23-PT   Belgium;Czech Republic;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002530-23-PL   Belgium;Czech Republic;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002530-23-NL   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002530-23-GB   Belgium;Czech Republic;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002530-23-FR   Belgium;Czech Republic;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002530-23-ES   Belgium;Czech Republic;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002530-23-DK   Belgium;Czech Republic;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002530-23-DE   Belgium;Czech Republic;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002530-23-CZ   Belgium;Czech Republic;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002530-23-BE   Belgium;Czech Republic;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2016   Phase 2   NCT02842242   United States;
      2014   Phase 1   NCT02329184   United States;
Magnetic resonance imaging (MRI) with gadolinium enhancement
   University Hospital, Bordeaux
      2015   -   NCT02559726   France;
Magnetic resonance imaging (MRI) without gadolinium enhancement
   University Hospital, Bordeaux
      2015   -   NCT02559726   France;
Mangafodipir
   University of Edinburgh
      2018   -   NCT03607669   United Kingdom;
Mavacamten
   LianBio LLC
      2022   Phase 3   NCT05174416   China;
      2021   Phase 1   NCT05135871   China;
   MYOKARDIA, INC.
      2018   Phase 3   EUCTR2017-002530-23-IT   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
   MyoKardia, Inc.
      2020   Phase 3   NCT04349072   United States;
      2018   Phase 3   NCT03470545   Belgium;Czechia;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2018   Phase 2/Phase 3   NCT03723655   Belgium;Czechia;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
      2018   Phase 2   NCT03496168   United States;
      2018   Phase 2   NCT03442764   United States;
Metoprolol
   The First Affiliated Hospital, Sun Yat-sen University
      2018   Phase 4 study   ChiCTR-IIR-17013661   China;
   University Hospital, Motol
      2020   Phase 4   NCT04133532   Czechia;
Metoprolol Succinate
   Steen Hvitfeldt Poulsen
      2018   Phase 2   NCT03532802   Denmark;
Metoprololsuccinat
   Aarhus University Hospital
      2018   Phase 2   EUCTR2017-004478-32-DK   Denmark;
Mitral regurgitation SE
   Fatebenefratelli Hospital
      2016   -   NCT03049995   Italy;
N-acetylcysteine
   The University of Texas Health Science Center, Houston
      2012   Phase 1   NCT01537926   United States;
NO
   West China Hospital, Sichuan University
      2019   -   ChiCTR1900021706   China;
PERINDOPRIL ARGININA
   AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI
      2017   Phase 2   EUCTR2015-004317-24-IT   Italy;
PROCAPTAN - 10 MG COMPRESSE RIVESTITE CON FILM 60 COMPRESSE IN CONTENITORE PER COMPRESSE PP
   AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI
      2017   Phase 2   EUCTR2015-004317-24-IT   Italy;
PROCAPTAN - 5 MG COMPRESSE RIVESTITE CON FILM 10 COMPRESSE IN CONTENITORE PER COMPRESSE PP
   AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI
      2017   Phase 2   EUCTR2015-004317-24-IT   Italy;
Perhexiline
   Flinders University
      2020   Phase 2   NCT04426578   Australia;
   Heart Metabolics Limited
      2015   Phase 3   NCT02431221   -
   University Hospital Birmingham
      2006   Phase 2   NCT00500552   United Kingdom;
Perindopril arginine
   AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI
      2017   Phase 2   EUCTR2015-004317-24-IT   Italy;
Perxexiline
   University Hospital of Birmingham Foundation Trust
      2005   -   EUCTR2005-000755-15-GB   United Kingdom;
Pexsig
   University Hospital of Birmingham Foundation Trust
      2005   -   EUCTR2005-000755-15-GB   United Kingdom;
Phosphorous
   University of East Anglia
      2017   Phase 1   NCT03251287   United Kingdom;
Pirfenidone
   National Heart, Lung, and Blood Institute (NHLBI)
      2001   Phase 2   NCT00011076   United States;
Pre and post-CPB Drug: Dobutamine Hydrochloride
   University Health Network, Toronto
      2021   Phase 4   NCT05025644   -
Pulmonary hemodynamics SE
   Fatebenefratelli Hospital
      2016   -   NCT03049995   Italy;
RANEXA - 750 MG - COMPRESSA A RILASCIO PROLUNGATO- USO ORALE - BLISTER (PVC/PVDC/ALLUMINIO) 60 COMPRESSE
   OSPEDALE SAN RAFFAELE
      2016   Phase 2   EUCTR2015-004402-42-IT   Italy;
RANEXA*60CPR 500MG R.P.
   MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.
      2012   Phase 2   EUCTR2011-004507-20-IT   Germany;Italy;Spain;
RANEXA*60CPR 750MG R.P.
   MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.
      2012   Phase 2   EUCTR2011-004507-20-IT   Germany;Italy;Spain;
RAS
   Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine
      2021   -   ChiCTR2000041243   China;
RF catheter ablation
   Institute of Cardiology, Warsaw, Poland
      2009   Phase 3   NCT00821353   Poland;
Ranexa
   Menarini International Operations Luxembourg S.A.
      2012   -   EUCTR2011-004507-20-ES   Germany;Italy;Spain;
      2012   -   EUCTR2011-004507-20-DE   Germany;Italy;Spain;
Ranolazina Ranexa
   OSPEDALE SAN RAFFAELE
      2016   Phase 2   EUCTR2015-004402-42-IT   Italy;
Ranolazine
   Duke University
      2012   Phase 4   NCT01721967   United States;
Ranolazine 1000 mg PR tablets
   Menarini International Operations Luxembourg S.A.
      2012   -   EUCTR2011-004507-20-ES   Germany;Italy;Spain;
      2012   -   EUCTR2011-004507-20-DE   Germany;Italy;Spain;
Ranolazine 500 mg PR tablets
   Menarini International Operations Luxembourg S.A.
      2012   -   EUCTR2011-004507-20-ES   Germany;Italy;Spain;
      2012   -   EUCTR2011-004507-20-DE   Germany;Italy;Spain;
Ranolazine 750 mg PR tablets
   Menarini International Operations Luxembourg S.A.
      2012   -   EUCTR2011-004507-20-ES   Germany;Italy;Spain;
      2012   -   EUCTR2011-004507-20-DE   Germany;Italy;Spain;
Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die
   IRCCS San Raffaele
      2016   Phase 2   NCT03953989   Italy;
Regadenoson
   Duke University
      2017   Phase 4   NCT03249272   United States;
SACUBITRIL VALSARTAN
   Novartis Farmacéutica, S.A.
      2020   Phase 2   EUCTR2019-003098-24-ES   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
   Novartis Pharma AG
      2020   Phase 2   EUCTR2019-003098-24-GR   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003098-24-GB   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003098-24-FI   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-003098-24-DE   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
Sacubitril/Valsartan
   Newcastle University
      2019   Phase 2   NCT03832660   Germany;Italy;Serbia;United Kingdom;
Sacubitril/valsartan
   Novartis Farmacéutica, S.A.
      2020   Phase 2   EUCTR2019-003098-24-ES   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
   Novartis Pharma AG
      2020   Phase 2   EUCTR2019-003098-24-GR   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003098-24-GB   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003098-24-FI   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-003098-24-DE   Finland;Germany;Greece;Korea, Republic of;Spain;United Kingdom;United States;
Spironolactone
   Tufts Medical Center
      2007   Phase 4   NCT00879060   United States;
   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
      2018   Phase 4   NCT02948998   China;
Surgical Septal Myectomy
   St. Antonius Hospital
      2021   -   NCT04684290   Netherlands;
TY-0305
   TOA EIYO LTD.
      2019   Phase 2   JPRN-JapicCTI-194910   Japan;
Trans-right ventricular alcohol septal ablation (TRVASA)
   National Heart, Lung, and Blood Institute (NHLBI)
      2002   Phase 2   NCT00035386   United States;
Treatment BX1514M
   University Hospital, Bordeaux
      2015   Phase 2   NCT02590809   France;
Trientine
   Manchester University NHS Foundation Trust
      2020   Phase 2   NCT04706429   United Kingdom;
      2020   Phase 2   EUCTR2020-002242-17-GB   United Kingdom;
Triethylinetetramine dihydrochloride
   Manchester University NHS Foundation Trust
      2020   Phase 2   EUCTR2020-002242-17-GB   United Kingdom;
Trimetazidine
   University College, London
      2012   Phase 2   NCT01696370   United Kingdom;
Use of bioanalytical assay to monitor plasma levels of perhexiline
   Heart Metabolics Limited
      2016   Phase 2   NCT02862600   United States;
Valsartan
   HealthCore-NERI
      2014   Phase 2   NCT01912534   Canada;United States;
Vastarel
   VU University Medical Center
      2018   Phase 2   EUCTR2018-000029-29-NL   Netherlands;
Vastarel 20mg film coated tablets
   University College London (UCL)
      2011   -   EUCTR2011-000038-12-GB   United Kingdom;